Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

Daniel O’Day is ex­e­cut­ing his first ma­jor de­vel­op­ment deal since tak­ing over as CEO of Gilead $GILD. And he’s go­ing in deep to al­ly him­self with a long­stand­ing part­ner.

O’Day an­nounced to­day that he is spend­ing $5 bil­lion in cash to add new late-stage drugs to Gilead’s pipeline, pick­ing up rights to Gala­pa­gos’ $GLPG Phase III IPF drug GLPG1690 along­side adop­tion of the biotech’s Phase IIb drug GLPG1972 for os­teoarthri­tis. And Gilead is al­so putting bil­lions more on the ta­ble for mile­stones, gain­ing op­tions for every­thing else in Gala­pa­gos’ pipeline, with a shot at all rights out­side of Eu­rope.

Al­to­geth­er, Gilead is gain­ing rights to 6 clin­i­cal-stage as­sets, 20 pre­clin­i­cal pro­grams and every­thing else be­ing hatched in trans­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER